Compare BHK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | PCRX |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.4M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | BHK | PCRX |
|---|---|---|
| Price | $8.95 | $23.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.20 |
| AVG Volume (30 Days) | 317.9K | ★ 797.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 1.03 | 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $7.10 |
| Revenue Next Year | N/A | $9.15 |
| P/E Ratio | ★ $8.79 | $145.63 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $9.01 | $18.80 |
| 52 Week High | $11.00 | $27.99 |
| Indicator | BHK | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.95 | 53.43 |
| Support Level | N/A | $22.57 |
| Resistance Level | $9.72 | $23.91 |
| Average True Range (ATR) | 0.08 | 0.85 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 3.31 | 64.63 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.